Details of the Drug

General Information of Drug (ID: DMN37M6)

Drug Name
LY3437943
Synonyms retatrutide
Indication
Disease Entry ICD 11 Status REF
Obesity 5B81 Phase 2 [1]
Type 2 diabetes 5A11 Phase 2 [2]
Drug Type
Peptide
Cross-matching ID
PubChem CID
171390338
TTD ID
DR76TW
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Gastric inhibitory polypeptide receptor (GIPR) TTYMKBE GIPR_HUMAN Agonist [3]
Glucagon receptor (GCGR) TT9O6WS GLR_HUMAN Agonist [3]
Glucagon-like peptide 1 receptor (GLP1R) TTVIMDE GLP1R_HUMAN Agonist [3]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

ICD Disease Classification 05 Endocrine, nutritional or metabolic disease
Disease Class ICD-11: 5A11 Type 2 diabetes mellitus
The Studied Tissue Liver tissue
The Studied Disease Type 2 diabetes [ICD-11:5A11]
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Gastric inhibitory polypeptide receptor (GIPR) DTT GIPR 6.53E-02 -0.19 -1.27
Glucagon-like peptide 1 receptor (GLP1R) DTT GLP1R 1.25E-01 0.17 1.26
Glucagon receptor (GCGR) DTT GCGR 7.24E-02 -0.52 -0.92
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 ClinicalTrials.gov (NCT04881760) A Phase 2 Study of Once-Weekly LY3437943 Compared With Placebo in Participants Who Have Obesity or Are Overweight With Weight-Related Comorbidities. U.S.National Institutes of Health.
2 ClinicalTrials.gov (NCT04867785) A Phase 2 Study of Once-Weekly LY3437943 Compared With Placebo and Dulaglutide in Participants With Type 2 Diabetes. U.S.National Institutes of Health.
3 LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. Cell Metab. 2022 Sep 6;34(9):1234-1247.e9.